Compare KDK & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KDK | DFTX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | KDK | DFTX |
|---|---|---|
| Price | $8.78 | $22.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $15.38 | ★ $38.50 |
| AVG Volume (30 Days) | 621.8K | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $236.00 | N/A |
| Revenue Next Year | $459.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.43 | $14.62 |
| 52 Week High | $11.35 | $26.25 |
| Indicator | KDK | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 60.63 |
| Support Level | $8.63 | $16.37 |
| Resistance Level | $9.45 | N/A |
| Average True Range (ATR) | 0.58 | 1.39 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 43.21 | 40.92 |
Kodiak AI Inc is engaged in the commercial trucking industry and the public sector, based on AI-powered autonomous vehicle technology.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).